Volume 5, Issue 9

New and Emerging MS Treatment Options

In this issue:

What do the current data show about hematopoietic stem cell transplant (HSCT) versus high efficacy DMT on MS outcomes? Have newer DMTs been proven more effective in reducing relapse rates, or is the jury still out? BTK inhibitors are a treatment target in B cell malignancies and a growing number of autoimmune disorders; do they have a place in MS? What do VEP and MTR outcome measures mean to the potential success of promising new remyelination therapies?

Exploring these questions is the focus of this issue of eMultipleSclerosis Review, guest authored by Dr. Cole Harrington from the Ohio State University’s Wexner Medical Center.

Learning objective:

  • Describe benefits of new and emerging treatments for MS.

Author:

Cole Harrington, MD, PhD
Cole Harrington, MD, PhD

Assistant Professor in Neurology
Department of Neurology
The Ohio State University Wexner Medical Center
Columbus, OH

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: September 20, 2023
Expiration date: September 19, 2025